http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5780433-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5bc5292a07e34d16eb1d033a16d3aec3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1767 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate | 1996-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1998-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_782e37be9f1f3d96314a87bef8eb58e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64065a8a7247613368326c2a8b4c73cd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55aa7baabf09b632ede2dc7dac75f9c3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db62b0779cfe60854afa37e720d6d06a |
| publicationDate | 1998-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-5780433-A |
| titleOfInvention | Use of α-conotoxin MII to treat disorders resulting from nicotine stimulated dopamine release |
| abstract | Neuronal nicotinic acetylcholine receptors (nAChRs) are believed to mediate nicotine addiction. In addition, stimulation of nAChRs modulates release of neurotransmitters including dopamine, norepinephrine and serotonin. Thus, pharmacological manipulation of nicotinic receptors has implications for a wide variety of disorders including psychotic, mood, movement and cognitive. For most nAChRs, there are no subtype selective ligands. However, alpha -conotoxin MII, a small peptide from the carnivorous marine snail Conus magus, was recently isolated. This peptide has been shown to be a specific antagonist for alpha 3 beta 2 nicotinic receptors. The peptide potently blocks part, but not all, of nicotine-stimulated dopamine release from rat brain striatal synaptosomes. In contrast it has no effect on potassium stimulated dopamine release. Other alpha -conotoxins specifically target distinct neuronal nAChR subtypes. alpha -Conotoxins thus represent new lead compounds for CNS disorders. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9921878-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8513281-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006211623-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004254477-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7387997-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009005316-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8101573-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003208042-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6958323-B2 |
| priorityDate | 1996-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 74.